Prevalence Of Syndrome In Patients Research Articles

Obesity-Hypoventilation Syndrome prevalence in patients with metabolic syndrome: intermediate analysis estimates obesity-related sleep hypoventilation prevalence at 6%

Obesity-Hypoventilation Syndrome prevalence in patients with metabolic syndrome: intermediate analysis estimates obesity-related sleep hypoventilation prevalence at 6%

The prevalence of metabolic syndrome in patients with hyperprolactinemia

The prevalence of metabolic syndrome in patients with hyperprolactinemia

Inflammatory markers and organ dysfunction in patients with severe influenza A (H1N1) virus-associated pneumonia

Aim. To assess inflammatory markers and organ dysfunction in patients with severe influenza A (H1N1) virus-associated pneumonia.Materials and Methods. The study included 50 patients (median age 47 (38-62) years, 24 males and 26 females) with severe influenza A (H1N1) virus-associated pneumonia. We analysed the clinicopathological data as well as complete blood count and biochemical profile. Organ dysfunction was assessed using SOFA and qSOFA scales.Results. The prevalence of multiple organ dysfunction syndrome in patients with severe influenza A (H1N1) virus-associated pneumonia was 46% (23/50 patients). Patients frequently suffered from insufficient oxygenation, impaired coagulation, altered haemodynamics, and central nervous system dysfunction. Out of 23 patients with multiple organ dysfunction syndrome, 10 (43.5%) suffered from reduced oxygenation and excessive coagulation, while 6 (26.0%) had all mentioned syndromes combined. Thrombocytopenia was detected as early as at day 1-2 of the disease and was further accompanied by an increase in the erythrocyte sedimentation rate and white blood cell count from day 2 to day 8. An increase in acute-phase proteins (C-reactive protein and fibrinogen) was noted at the day 5-6 of the disease.Conclusion. In patients with severe influenza A (H1N1) virus-associated pneumonia, an early systemic inflammatory response evolves into an uncontrolled multiple organ dysfunction syndrome by day 7-8 of infection.

The effect of the COVID-19 pandemic period on the prevalence of metabolic syndrome in patients with schizophrenia and bipolar disorder

The effect of the COVID-19 pandemic period on the prevalence of metabolic syndrome in patients with schizophrenia and bipolar disorder

Prevalence and impact of metabolic syndrome in patients with multivessel coronary artery disease and acute coronary syndrome

Abstract Background Metabolic syndrome is associated with increased incidence of diabetes and cardiovascular diseases in patients initially free from these diseases. However, its prognostic value in patients with established coronary artery diseases remains controversial. Purpose Therefore, we aimed to illustrate the prevalence and investigate the impact of metabolic syndrome in patients with multivessel coronary artery disease and acute coronary syndrome. Methods We conducted a large registry of consecutive patients with acute coronary syndrome referred to primary percutaneous coronary intervention and those with multivessel diseases were eligible for this analysis. Metabolic syndrome was defined using modified criteria based on the Adult Treatment Panel III definition from the National Cholesterol Education Program. The primary outcome was major adverse cardiovascular events (MACE), a composite of all-cause death, myocardial infarction, and stroke. Results A total of 2532 patients were included in current analysis and 993 (39.2%) of them had metabolic syndrome while 1539 (60.8%) did not. The prevalence of metabolic syndrome increased over the study period (p for trend = 0.005). There was a significant decline of metabolic syndrome prevalence in patients over 60 years old (p for trend = 0.002) and females had a higher prevalence than their male counterparts (61.5% verse 32.9%, p<0.001). Over a median follow-up of 2.3 years, metabolic syndrome was not significantly associated with MACE (adjusted 95% CI 0.92 to 1.54). In addition, there was no significant difference observed between two groups in other individual outcomes, namely all-cause death, cardiac death, stroke, myocardial infarction, and any revascularization. Conclusions Metabolic syndrome was frequently observed in patients with multivessel coronary artery disease and acute coronary syndrome. Patients with metabolic syndrome were more likely to be young and female. However, it was not an independent predictor for MACE after primary percutaneous coronary intervention in those patients. Funding Acknowledgement Type of funding sources: Public Institution(s). Main funding source(s): Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences Metabolic syndrome distribution in MVDOutcome according to metabolic syndrome

Comparative Characteristics of the Metabolic Syndrome Prevalence in Patients With Schizophrenia in Three Western Siberia Psychiatric Hospitals.

Objective: The purpose of this study was to compare the prevalence of MetS and the associated sociodemographic, clinical, and pharmacotherapeutic characteristics of patients with schizophrenia in three psychiatric hospitals in the West Siberian region.Methods: Patients with a clinical diagnosis of schizophrenia (ICD-10: F20) and an age between 18 and 60 years were included in the study after giving informed consent. Metabolic syndrome was diagnosed according to the International Diabetes Federation criteria. This research was carried out at three Western Siberian psychiatric hospitals in Kemerovo, Tomsk, and Omsk. The study population included respectively 94, 131, and 91 inpatients with schizophrenia. We carried out schizophrenia symptoms assessment by PANSS, antipsychotic therapy evaluation, anthropometry, and biochemical analysis. Statistical Analysis included the Shapiro–Wilk test, non-parametric Kruskal–Wallis H-test for independent samples, Mann–Whitney U-test for independent samples, the chi-square test, stepwise multiple regression analyses. The level of significance was p < 0.05.Results: The metabolic syndrome prevalence was higher among patients in Tomsk (36.6%), compared with Kemerovo (20.2%, p = 0.008) or Omsk (18.7%, p = 0.004), mainly due to the high prevalence of abdominal obesity, while men from Tomsk were more susceptible to this condition than men from other regions (p < 0.05). Patients from Omsk had the highest severity schizophrenia symptoms according to PANSS, and patients from Tomsk had the lowest severity of positive symptoms according to PANSS. Patients from Tomsk had the minimum duration of antipsychotic therapy compared with the patient from Kemerovo (p = 0.017) and from Omsk (p = 0.000019), but most patients from Tomsk received second-generation atypical antipsychotics, while patients from Omsk received mainly conventional antipsychotics (p = 0.0001). Multiple regression analysis showed that metabolic syndrome associated with schizophrenia duration and body mass index, although the association was not so strong (adjusted R2 = 0.2435, p < 0.0001).Discussion: The study illustrates that in different psychiatric hospitals within the same region, the prevalence of metabolic syndrome in patients with schizophrenia can vary significantly, which dictates the need to look for opportunities to minimize the risk of its occurrence, taking into account the experience of each hospital.

Metabolic syndrome in patients with Alopecia Areata: A case-control study.

The aim of this study was to evaluate metabolic syndrome prevalence in patients with Alopecia Areata compared to controls. Sixty eligible patients with Alopecia Areata and 60 healthy subjects frequency matched for age and sex attending to our referral dermatology clinics from 2015 to 2017 were enrolled. Prevalence of metabolic syndrome and its components were compared between the two groups. Metabolic syndrome was only seen in seven patients (11.67%) and four controls (6.67%) without a significant difference (P= .34). The clinical presentations of AA included patch type (38.33%), ophiasis (6.67%), alopecia totalis (16.67%), and alopecia universalis (38.33%). Presence of metabolic syndrome was significantly associated with abdominal circumference (OR: 1.10, 95% CI for OR: 1.02to 1.19). Although there was no significant association between Alopecia Areata and metabolic syndrome, some components of metabolic syndrome were more prevalent in these patients. It may be concluded Alopecia Areata patients are at a higher risk of developing metabolic syndrome in the future. Further studies with larger sample sizes are needed.

Prevalence of metabolic syndrome in patients with schizophrenia

Prevalence of metabolic syndrome in patients with schizophrenia

The Relationship between Recurrent Aphthous Stomatitis and Metabolic Syndrome

Metabolic syndrome or X syndrome includes a group of metabolic and non-metabolic disorders, that increase the risk of some disease. This study aimed to determine the prevalence of metabolic syndrome in healthy subjects and patients with recurrent aphthous stomatitis (RAS) was conducted. In this cross-sectional study 33 patients with recurrent aphthous stomatitis which were referred to Department of Oral Medicine of Tabriz dental school were studied. The inclusion criteria included consent to participates in the study, lack of underlying disease associated with RAS such as Behcet’s syndrome and lack of systemic diseases. RAS patients were examined in terms of risk of the metabolic syndrome and 33 age and sex matched healthy individuals were selected and examined in terms of risk of metabolic syndrome. Data samples from check list contain demographic and laboratory findings were collected. Results showed that the prevalence of metabolic syndrome in patients with RAS (21.2%) was significantly higher than in healthy people (9.1%). (p&lt;0.05) Female percentage of RAS patients with metabolic syndrome were 71.4 and Male percentage of RAS patients with metabolic syndrome were 28.6. Given the high prevalence of metabolic syndrome in patients with RAS, this syndrome can be considered as a risk factor for RAS.

Metabolic syndrome prevalence in patients with obstructive sleep apnea syndrome and chronic obstructive pulmonary disease: Relationship with systemic inflammation.

ObjectivesMetabolic syndrome (MetS) is frequent in both chronic obstructive pulmonary disease (COPD) and Obstructive sleep apnea (OSA). The aim of this study was to assess the frequency of MetS and the status of systemic inflammation in overlap syndrome.MethodsA total of 151 consecutive COPD patients were recruited in this cross‐sectional study. Spirometry and polysomnography were done in all patients. The MetS was defined according to the criteria of the International Diabetes Federation. Anthropometry, metabolic parameters and inflammatory biomarkers: IL‐6, TNF‐α, leptin, resistin and adiponectin were recorded.ResultsOSA was present in 19.2% COPD patients. Subjects with overlap syndrome had higher neck and waist circumference compared to those with COPD alone. Significant differences in levels of blood pressure, lipid metabolic and glucose metabolic were found between two groups with overlap and COPD, as well as inflammatory biomarkers. Prevalence of MetS was increased in overlap group. Multivariate logistic regression showed that BMI, systolic BP when fall asleep and recumbent angiotens levels as significant independent predictors of the presence of Mets in overlap syndrome.ConclusionThis study shows that MetS is frequent in patients with overlap. Overlap syndrome indicates a higher cardiometabolic risk and higher levels of systemic inflammatory.

PREVALÊNCIA DE SÍNDROME METABÓLICA E PERFIL NUTRICIONAL DE PACIENTES OBESOS CARDIOPATAS HOSPITALIZADOS

A Síndrome metabólica é considerada uma doença crônica não transmissível complexa, associada a um conjunto de riscos cardiometabólicos, dentre eles: dislipidemias, intolerância à glicose, resistência à insulina, hipertensão e obesidade. Objetivos: Avaliar a prevalência de Síndrome Metabólica e o perfil nutricional de pacientes obesos cardiopatas de um Hospital Universitário. Estudo transversal com 33 pacientes obesos cardiopatas de um hospital universitário de Campo Grande – MS. Avaliou-se: peso, altura, circunferência da cintura, inquérito de frequência alimentar, pressão arterial, glicose em jejum, níveis séricos de HDL-c e de triglicerídeos. Para prevalência da SM utilizou-se critérios do National Cholesterol Education Program’s Adult Treatment Panel III (NCEP-ATP III, 2002). Foi utilizado o software SPSS, considerando nível de significância de 5%. Resultados: O tipo de cardiopatia e co-morbidade mais frequentes foram Infarto Agudo do Miocárdio (30,3%) e a hipertensão (36,6%), respectivamente. Quanto ao perfil nutricional, clínico e bioquímico, todos os participantes apresentaram elevados níveis de circunferência da cintura, de glicose de jejum e de triglicerídeos, bem como, reduzido nível de HDL-c, porém sem diferença significativa entre os grupos adultos e idosos. Não foram identificadas diferenças significativas no consumo alimentar entre os grupos avaliados. Verificou-se alta prevalência de Síndrome Metabólica nos obesos cardiopatas avaliados (84,85%), sendo 85,71% entre os adultos e 100% entre os idosos. Conclusões: A associação de alterações no perfil nutricional, clínico e bioquímico, que caracterizaram a alta prevalência de síndrome metabólica nos pacientes avaliados, juntamente com os fatores hereditários, reforçam a necessidade de implantação de medidas preventivas para atenuar essa condição.

Metabolic syndrome, depression, and fibromyalgia syndrome prevalence in patients with irritable bowel syndrome: A case-control study.

Although both metabolic syndrome (MetS) and irritable bowel syndrome (IBS) have been linked with altered gut microbiota, only a few studies investigated the association between them. Hence, we aimed to evaluate the prevalence of MetS along with depression and fibromyalgia syndrome (FMS) in IBS patients.This was a case-control study in which 3808 consecutive patients who attended outpatient clinics of Erzurum Regional Training and Research Hospital between May 2019 and August 2019 were evaluated in terms of IBS with Rome-IV criteria. Out of 486 patients who were diagnosed as IBS, 176 patients were excluded for various reasons. Control subjects were randomly selected from IBS-negative subjects. MetS was diagnosed based on International Diabetes Federation criteria. Depression, anxiety disorder, and FMS were assessed via Hamilton Depression Scale, Beck Anxiety Inventory, and American College of Rheumatology criteria, respectively. Blood samples were obtained to measure biochemical parameters.Study group included 310 IBS patients, and control group included 304 subjects. The prevalence of the MetS was significantly higher among IBS patients compared with controls (36.8% vs 21.7%, respectively, P = .006). The rate of obesity was 18.1% among IBS subjects, and 10.2% in the controls. The prevalence of fibromyalgia (30% vs 3%, respectively, P < .001), anxiety-disorder (39.7% vs 10.2%, P < .001) and depression (8.1% vs 4.9%, P < .001) were significantly higher in IBS group than controls.Metabolic syndrome and obesity were significantly more frequent in IBS patients compared with controls. FMS, anxiety disorder, and depression were also more common among IBS patients.

The Prevalence of Metabolic Syndrome in Patients with Euthyroid Autoimmune Thyroiditis

The Prevalence of Metabolic Syndrome in Patients with Euthyroid Autoimmune Thyroiditis

Prevalence of Metabolic Syndrome in Patients with Ankylosing Spondylitis

Prevalence of Metabolic Syndrome in Patients with Ankylosing Spondylitis

2463-PUB: Prevalence of Metabolic Syndrome in Patients with Type 1 Diabetes: Impact on Microvascular Complications and Subclinical Inflammation

Introduction: The MS might also be present in patients with DM1 worsening vascular prognosis. Objective: We aimed to determine the prevalence of MS and its association with microvascular disease and to describe the differences between patients with or without MS in markers of subclinical inflammation and adiposity. Methods: A cross-sectional study including 289 consecutive patients with DM1. MS was defined according to the criteria of the IDF but for the presence of fasting hyperglycemia or diabetes. Microvascular complications were assessed according to ADA. Serum inflammation markers such as high hsCRP, ESR, homocystein and fibrinogen were measured. Results: The mean age was 36 ± 12 years-old. 40% were female. Duration of DM1 was 20 ± 11 years. The mean HbA1c was 7.6±1.3% and the GFR was 94±18 ml/min/1.73m2. The prevalence of MS, as defined, was 12.5% (95% CI: 9.1 - 16.8). The odds of having microvascular complications was 2.4 higher among MS+ group [OR: 2.4 (1.0-5.7); P = 0.042] compared with MS- group, after adjusting for age and DM1 duration. Adiposity and markers of subclinical inflammation were significantly higher in MS+ group compared to their MS- counterparts (Table 1). Conclusions: The prevalence of MS was considerable in patients with DM1. MS was an independent risk factor for the presence of microvascular complications regardless of age and DM1 duration. The presence of MS in patients with DM1 is associated with adiposity and subclinical inflammation. Disclosure E. Lecumberri: None. M. Luque-Ramírez: None. J. Quiñones Silva: None. E. Fernández: None. S. Alonso Diaz: None. H. Escobar-Morreale: None. L. Nattero-Chávez: None. Funding Instituto de Salud Carlos III, Spanish Ministry of Economy and Competitiveness (PI1400649, PI151686, PIE1600050)

Prevalence of Metabolic Syndrome in Patients with Lichen Planus: A Cross-Sectional Study from a Tertiary Care Center.

Prevalence of Metabolic Syndrome in Patients with Lichen Planus: A Cross-Sectional Study from a Tertiary Care Center.

Study of Lipid Profile in Different grades of Non- Alcoholic Fatty Liver Disease

Background: The prevalence of NAFLD (non- alcoholic fatty liver disease) is increasing as it exceed (31.79%) in Middle East and the metabolic syndrome prevalence in patients with NAFLD ranges from 18% to 67%, according to the body weight. Imaging or histology is very important tools in diagnosis of NAFLD. Early detection of NAFLD is very important especially if there is a non-invasive method. The clinicians in the primary, secondary and tertiary care are in need for specific and sensitive diagnostic tool that can be used easily. Aim: To study and analyze serum lipid changes in non-alcoholic fatty liver disease of different grades. Patients and methods: 100 patients diagnosed by ultrasonography as NAFLD, whose age was more than 18 years, were included in the study. History taking, full clinical examination and anthropometric measurement of weight, height and body mass index (BMI) were done for all patients. Serum lipid profiles including total cholesterol, HDL, LDL, triglycerides, ALT, AST. CBC, fasting and 2hpp blood glucose and TSH were measured. Results: The largest group of patients (38%) was in the fifth decade of life. followed by 30% in the sixth decade of life. As the grade of NAFLD increased, there was associated significant increase in levels of serum total cholesterol (P-value 0.005), TG (P-value 0.002) LDL (P-value 0.001) and VLDL (P-value 0.003) and associated significant decrease in HDL (P-value 0.001). Conclusions: abdominal ultrasonography and increased lipid profile values can be used to detect NAFLD early

Features of treatment of patients with psoriasis with metabolic syndrome

The article provides information on the prevalence of metabolic syndrome in patients with psoriasis. The criteria for the diagnosis of metabolic syndrome are presented. The General mechanisms of inflam - mation development in psoriasis and diseases forming the metabolic syndrome are described. Systemic subclinical inflammatory process developing in psoriasis and metabolic syndrome is considered as the main pathogenetic mechanism of their mutual negative influence. The difficulties of treatment of patients with psoriasis with metabolic syndrome are largely associated with the choice of a safe and effective method of treatment. The description of the drug apremilast (OTEZLA®) is a selective inhibitor of the enzyme phosphodiesterase 4, which may be the best drug in the therapy of patients with psoriasis and metabolic syndrome.

The prevalence of metabolic syndrome in patients receiving antipsychotics in Qatar: a cross sectional comparative study

BackgroundMetabolic abnormalities are common in patients maintained on antipsychotics. These abnormalities increase the risk of cardiovascular diseases and mortality in this population. The aim of this study is to assess the prevalence of metabolic syndrome (MetS) in subjects maintained on antipsychotics relative to controls in Qatar, and to assess the factors contributing to the development of MetS.MethodsA cross sectional design was used to collect data and fasting blood samples from subjects maintained on antipsychotics for at least six months (n = 112) and from a control group (n = 114). The groups were compared in regard to prevalence of MetS, and multiple regression analysis was used to determine the risk factors in each group.ResultsThe two groups (antipsychotics vs. control) were similar in regard to age (35.73 ± 10.28 vs. 35.73 ± 8.16 years) and gender ratio. The MetS was higher among the subjects on antipsychotics, but this difference did not reach statistical significance. Blood pressure (BP) was significantly higher in the antipsychotics group and BMI was the major risk factor to develop MetS in this group.ConclusionsThe prevalence of MetS in both groups is high and mostly attributed to obesity and high BP. Public health interventions are needed to address this major health problem overall. Larger studies are needed to further assess the impact of antipsychotics and mental illness on the development of MetS.

Comparison of the prevalence of metabolic syndrome in patients with schizophrenia and bipolar disorder: a cross-sectional study from Black Sea region

Objective: Previous research has suggested that metabolic syndrome is more prevalent among patients with schizophrenia and bipolar disorder. Given the scarcity of comparative research on these disorders, this study aims to compare the prevalence of metabolic syndrome in two diagnostic groups and to identify sociodemographic or clinical factors related to metabolic syndrome. Methods: A total of 235 patients diagnosed with schizophrenia (n=160) and bipolar disorder (n=75) and were being followed up by a metabolic monitoring program in a specialized outpatient clinic and using antipsychotic therapy for at least eight weeks have participated in this cross-sectional study. Patients were diagnosed with metabolic syndrome according to National Cholesterol Education Program Adult Treatment Panel-III (NCEP ATP-III) criteria. Sociodemographic and clinical data including metabolic records were collected retrospectively by reviewing the patients’ medical records. Results: The overall prevalence of meta-bolic syndrome was 32.3% and waist circumference was the most frequent individual component with a prevalence of 60%. There were no differences in the prevalence of metabolic syndrome between schizophrenia and bipolar patients. Age, body mass index (BMI), and use of certain types of atypical antipsychotics were found related to metabolic syndrome. Conclusion: The prevalence of metabolic syndrome and its components among patients with severe mental illness is alarming irrespective of their diagnoses. Thus, metabolic screening is crucial especially for high-risk groups.